Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...

The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies ...

Stelara is a brand-name drug prescribed for certain autoimmune conditions. Discover drug interactions in-depth, vaccine interactions, and more.

Stelara was approved in 2016 to treat Crohn’s disease and in 2019 for ulcerative colitis. ... you will receive a shot every eight weeks. ...

Otulfi is supplied as a 45mg/0.5mL and a 90mg/mL single-dose prefilled syringe for subcutaneous injection, a 45mg/0.5mL single-dose vial for subcutaneous injection, and a 130mg/26mL single-dose ...

GUANGZHOU, China and LONDON, May 27, 2025/ PRNewswire/-- Bio-Thera Solutions, Ltd, a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma ...

Selarsdi is FDA-approved in all Stelara-equivalent forms for psoriasis, arthritis, Crohn's, and colitis. Three biosimilar BLAs from Teva-Alvotech are under FDA review, with approvals expected in ...

Medicare beneficiaries face higher costs for Johnson & Johnson's Stelara due to a shift in coverage from Part B to Part D. The OIG report shows a nearly tenfold increase in Medicare spending on ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...

Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies ...